Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chantale Morin is active.

Publication


Featured researches published by Chantale Morin.


Cell Cycle | 2013

The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion

Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov

Previously, we have identified the RUNX1 gene as hypomethylated and overexpressed in post-chemotherapy (CT) primary cultures derived from epithelial ovarian cancer (EOC) patients, when compared with primary cultures derived from matched primary (prior to CT) tumors. Here we show that RUNX1 displays a trend of hypomethylation, although not significant, in omental metastases compared with primary EOC tumors. Surprisingly, RUNX1 displayed significantly higher expression not only in metastatic tissue, but also in high-grade primary tumors and even in low malignant potential tumors. The RUNX1 expression levels were almost identical in primary tumors and omental metastases, suggesting that RUNX1 hypomethylation might have a limited impact on its overexpression in advanced (metastatic) stage of the disease. Knockdown of the RUNX1 expression in EOC cells led to sharp decrease of cell proliferation and induced G1 cell cycle arrest. Moreover, RUNX1 suppression significantly inhibited EOC cell migration and invasion. Gene expression profiling and consecutive network and pathway analyses confirmed these findings, as numerous genes and pathways known previously to be implicated in ovarian tumorigenesis, including EOC tumor invasion and metastasis, were found to be downregulated upon RUNX1 suppression, while a number of pro-apoptotic genes and some EOC tumor suppressor genes were induced. Taken together, our data are indicative for a strong oncogenic potential of the RUNX1 gene in EOC progression and suggest that RUNX1 might be a novel EOC therapeutic target. Further studies are needed to more completely elucidate the functional implications of RUNX1 and other members of the RUNX gene family in ovarian tumorigenesis.


PLOS ONE | 2013

Inhibition of RUNX2 Transcriptional Activity Blocks the Proliferation, Migration and Invasion of Epithelial Ovarian Carcinoma Cells

Zhi-Qiang Wang; Mamadou Keita; Magdalena Bachvarova; Stéphane Gobeil; Chantale Morin; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov

Previously, we have identified the RUNX2 gene as hypomethylated and overexpressed in post-chemotherapy (CT) primary cultures derived from serous epithelial ovarian cancer (EOC) patients, when compared to primary cultures derived from matched primary (prior to CT) tumors. However, we found no differences in the RUNX2 methylation in primary EOC tumors and EOC omental metastases, suggesting that DNA methylation-based epigenetic mechanisms have no impact on RUNX2 expression in advanced (metastatic) stage of the disease. Moreover, RUNX2 displayed significantly higher expression not only in metastatic tissue, but also in high-grade primary tumors and even in low malignant potential tumors. Knockdown of the RUNX2 expression in EOC cells led to a sharp decrease of cell proliferation and significantly inhibited EOC cell migration and invasion. Gene expression profiling and consecutive network and pathway analyses confirmed these findings, as various genes and pathways known previously to be implicated in ovarian tumorigenesis, including EOC tumor invasion and metastasis, were found to be downregulated upon RUNX2 suppression, while a number of pro-apoptotic genes and some EOC tumor suppressor genes were induced. Taken together, our data are indicative for a strong oncogenic potential of the RUNX2 gene in serous EOC progression and suggest that RUNX2 might be a novel EOC therapeutic target. Further studies are needed to more completely elucidate the functional implications of RUNX2 and other members of the RUNX gene family in ovarian tumorigenesis.


Canadian Journal of Plant Science | 2012

SHORT COMMUNICATION: Diurnal variations of nonstructural carbohydrates and nutritive value in timothy

Chantale Morin; Gilles Bélanger; Gaëtan F. Tremblay; Annick Bertrand; Yves Castonguay; Raynald Drapeau; Réal Michaud; R. Berthiaume; Guy Allard

Morin, C., Bélanger, G., Tremblay, G. F., Bertrand, A., Castonguay, Y., Drapeau, R., Michaud, R., Berthiaume, R. and Allard, G. 2012. Short Communication: Diurnal variations of nonstructural carbohydrates and nutritive value in timothy. Can. J. Plant Sci. 92: 883-887. Nonstructural carbohydrate (NSC) concentration in timothy (Phleum pratense L.) increased during the day by 16 to 41 g kg-1 DM (+23 to 137%) in spring and summer growth cycles and reached a maximum value between 12.8 and 13.2 h after sunrise in an area with 15 to 16 h of day length. This increase in NSC concentration was generally accompanied by a decrease in concentrations of neutral detergent fiber (-2 to 6%), acid detergent fiber (-1 to 7%), and N (-6 to 11%).


Oncotarget | 2016

The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells

Adnen Faddaoui; Magdalena Bachvarova; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Alexandra Sebastianelli; Stéphane Gobeil; Chantale Morin; Elizabeth Macdonald; Barbara C. Vanderhyden; Dimcho Bachvarov

The molecular basis of epithelial ovarian cancer (EOC) dissemination is still poorly understood. Previously, we identified the mannose receptor LY75 gene as hypomethylated in high-grade (HG) serous EOC tumors, compared to normal ovarian tissues. LY75 represents endocytic receptor expressed on dendritic cells and so far, has been primarily studied for its role in antigen processing and presentation. Here we demonstrate that LY75 is overexpressed in advanced EOC and that LY75 suppression induces mesenchymal-to-epithelial transition (MET) in EOC cell lines with mesenchymal morphology (SKOV3 and TOV112), accompanied by reduction of their migratory and invasive capacity in vitro and enhanced tumor cell colonization and metastatic growth in vivo. LY75 knockdown in SKOV3 cells also resulted in predominant upregulation of functional pathways implicated in cell proliferation and metabolism, while pathways associated with cell signaling and adhesion, complement activation and immune response were mostly suppressed. Moreover, LY75 suppression had an opposite effect on EOC cell lines with epithelial phenotype (A2780s and OV2008), by directing epithelial-to-mesenchymal transition (EMT) associated with reduced capacity for in vivo EOC cell colonization, as similar/identical signaling pathways were reversely regulated, when compared to mesenchymal LY75 knockdown EOC cells. To our knowledge, this is the first report of a gene displaying such pleiotropic effects in sustaining the cellular phenotype of EOC cells and points to novel functions of this receptor in modulating EOC dissemination. Our data also support previous findings regarding the superior capacity of epithelial cancer cells in metastatic colonization of distant sites, compared to cancer cells with mesenchymal-like morphology.


Cell Cycle | 2017

Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells

Adnen Faddaoui; Razan Sheta; Magdalena Bachvarova; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Alexandra Sebastianelli; Stéphane Gobeil; Chantale Morin; Karim Ghani; Dimcho Bachvarov

ABSTRACT Previously, we have identified the Grainyhead transcription factor 2 gene (GRHL2) as notably hypomethylated in high-grade (HG) serous epithelial ovarian tumors, compared with normal ovarian tissues. GRHL2 is known for its functions in normal tissue development and wound healing. In the context of cancer, the role of GRHL2 is still ambiguous as both tumorigenic and tumor suppressive functions have been reported for this gene, although a role of GRHL2 in maintaining the epithelial status of cancer cells has been suggested. In this study, we report that GRHL2 is strongly overexpressed in both low malignant potential (LMP) and HG serous epithelial ovarian tumors, which probably correlates with its hypomethylated status. Suppression of the GRHL2 expression led to a sharp decrease in cell proliferation, migration and invasion and induced G1 cell cycle arrest in epithelial ovarian cancer (EOC) cells displaying either epithelial (A2780s) or mesenchymal (SKOV3) phenotypes. However, no phenotypic alterations were observed in these EOC cell lines following GRHL2 silencing. Gene expression profiling and consecutive canonical pathway and network analyses confirmed these data, as in both these EOC cell lines, GRHL2 ablation was associated with the downregulation of various genes and pathways implicated in cell growth and proliferation, cell cycle control and cellular metabolism. Taken together, our data are indicative for a strong oncogenic potential of the GRHL2 gene in EOC progression and support recent findings on the role of GRHL2 as one of the major phenotypic stability factors (PSFs) that stabilize the highly aggressive/metastatic hybrid epithelial/mesenchymal (E/M) phenotype of cancer cells.


Gynecologic oncology reports | 2017

Proposed novel nomenclature of vulvar smooth muscle tumors; a case of Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP) of the vulva.

Mathieu Viau; Marie Plante; Marie-Claude Renaud; Katherine Grondin; Chantale Morin

Highlights • Clinical experience with smooth muscle tumors of the vulva is limited.• Some tumors present ambiguous histological features concerning for malignancy.• These include infiltration, mitotic activity, size, atypia and tumor cell necrosis.• A case of smooth muscle tumor of the vulva with cellular atypia is presented.• “Smooth Muscle Tumor of Uncertain Malignant Potential” of the vulva is advocated.


Oncotarget | 2017

Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner

Razan Sheta; Zhi-Qiang Wang; Magdalena Bachvarova; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Alexandra Sebastianelli; Stéphane Gobeil; Chantale Morin; Elizabeth Macdonald; Barbara C. Vanderhyden; Dimcho Bachvarov

The molecular basis of epithelial ovarian cancer (EOC) dissemination is still poorly understood. We have previously identified the hydrogen peroxide-inducible clone-5 (Hic-5) gene as hypomethylated in high-grade (HG) serous EOC tumors, compared to normal ovarian tissues. Hic-5 is a focal adhesion scaffold protein and has been primarily studied for its role as a key mediator of TGF-β–induced epithelial-to-mesenchymal transition (EMT) in epithelial cells of both normal and malignant origin; however, its role in EOC has been never investigated. Here we demonstrate that Hic-5 is overexpressed in advanced EOC, and that Hic-5 is upregulated upon TGFβ1 treatment in the EOC cell line with epithelial morphology (A2780s), associated with EMT induction. However, ectopic expression of Hic-5 in A2780s cells induces EMT independently of TGFβ1, accompanied with enhancement of cellular proliferation rate and migratory/invasive capacity and increased resistance to chemotherapeutic drugs. Moreover, Hic-5 knockdown in the EOC cells with mesenchymal morphology (SKOV3) was accompanied by induction of mesenchymal-to-epithelial transition (MET), followed by a reduction of their proliferative, migratory/invasive capacity, and increased drugs sensitivity in vitro, as well as enhanced tumor cell colonization and metastatic growth in vivo. The modulation of Hic-5 expression in EOC cells resulted in altered regulation of numerous EMT-related canonical pathways and was indicative for a possible role of Hic-5 in controlling EMT through a RhoA/ROCK mediated mechanism. To our knowledge, this is the first report examining the role of Hic-5 in EOC, and its role in maintaining the mesenchymal phenotype of EOC cells independently of exogenous TGFβ1 treatment.


Oncotarget | 2014

Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation

Zhi-Qiang Wang; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Alexandra Sebastianelli; Dimcho Bachvarov


Crop Science | 2011

Diurnal Variations of Nonstructural Carbohydrates and Nutritive Value in Alfalfa

Chantale Morin; Gilles Bélanger; Gaëtan F. Tremblay; Annick Bertrand; Yves Castonguay; Raynald Drapeau; Réal Michaud; R. Berthiaume; Guy Allard


Crop Science | 2014

Silage Fermentation of PM- and AM-Cut Alfalfa Wilted in Wide and Narrow Swaths

Gaëtan F. Tremblay; Chantale Morin; Gilles Bélanger; Annick Bertrand; Yves Castonguay; R. Berthiaume; Guy Allard

Collaboration


Dive into the Chantale Morin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Annick Bertrand

Agriculture and Agri-Food Canada

View shared research outputs
Top Co-Authors

Avatar

Gaëtan F. Tremblay

Agriculture and Agri-Food Canada

View shared research outputs
Top Co-Authors

Avatar

Gilles Bélanger

Agriculture and Agri-Food Canada

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge